140 related articles for article (PubMed ID: 33348943)
1. Hard-to-treat psoriasis in a child developing neutralizing anti-drug antibodies against adalimumab during Streptococcus pyogenes throat infection: a case report.
Starbek Zorko M; Selan M
Acta Dermatovenerol Alp Pannonica Adriat; 2020 Dec; 29(4):219-222. PubMed ID: 33348943
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
[TBL] [Abstract][Full Text] [Related]
3. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
Sorenson E; Koo J
J Dermatolog Treat; 2015; 26(6):493-501. PubMed ID: 25886082
[TBL] [Abstract][Full Text] [Related]
5. Antidrug antibodies in psoriasis: a systematic review.
Hsu L; Snodgrass BT; Armstrong AW
Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
7. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
8. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
9. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
10. Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial.
Atalay S; Berends SE; Groenewoud HMM; Mathot RAA; Njoo DM; Mommers JM; Ossenkoppele PM; Koetsier MIA; Berends MA; de Vries A; van de Kerkhof PCM; den Broeder AA; de Jong EMGJ; van den Reek JMPA
J Dermatolog Treat; 2022 Aug; 33(5):2680-2684. PubMed ID: 35193441
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study.
Wu JJ; Guérin A; Gauthier G; Sundaram M
J Dermatolog Treat; 2017 Jun; 28(4):290-298. PubMed ID: 27783534
[TBL] [Abstract][Full Text] [Related]
12. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
[TBL] [Abstract][Full Text] [Related]
13. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for pediatric psoriasis.
Schwartz G; Paller AS
Semin Cutan Med Surg; 2018 Sep; 37(3):167-172. PubMed ID: 30215634
[TBL] [Abstract][Full Text] [Related]
15. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
[TBL] [Abstract][Full Text] [Related]
16. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
17. Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics.
Tokuyama M; Ota M; Saitoh R; Sawamura M; Okitsu N; Shimizu T; Kondoh A; Yamaoka H; Mabuchi T
Tokai J Exp Clin Med; 2020 Dec; 45(4):230-235. PubMed ID: 33300595
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department.
Roche H; Bouiller K; Puzenat E; Deveza E; Roche B; Pelletier F; van de Laak A; Dupond AS; Nardin C; Aubin F
J Dermatolog Treat; 2019 Sep; 30(6):540-544. PubMed ID: 29848153
[No Abstract] [Full Text] [Related]
19. Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.
D'Amico F; Trovato C; Skarmoutsou E; Rossi GA; Granata M; Longo V; Gangemi P; Pettinato M; Mazzarino MC
J Dermatol Sci; 2015 Oct; 80(1):38-44. PubMed ID: 26276441
[TBL] [Abstract][Full Text] [Related]
20. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
